web analytics
16.6 C
Munich
Thursday, October 6, 2022
type here...

TAG

enzc

BioPharma

Enzolytics Inc (OTCMKTS: ENZC) Coiled Tight Near 52 Week Lows as Biotech Looks to Disrupt Several Enormous Markets (ITV-1 for HIV, Monoclonal Antibodies &...

Boe Rimes -
Enzolytics Inc (OTCMKTS: ENZC) is holding strong at support levels in the high $0.05's as the overall markets have seen significant declines. ENZC was...
BioPharma

Enzolytics Inc (OTCMKTS: ENZC) Powerful Reversal Underway as Immune™ Goes International in Booming Nutritional Supplement Market

Boe Rimes -
Enzolytics Inc (OTCMKTS: ENZC) is making a powerful move up the charts in recent days since reversing off $0.06 support levels, the second time...
Street Watch

Enzolytics Inc (OTCMKTS: ENZC) Running Up the Charts After Biotech Outlines Progress and Future Plans (Update on: Artificial Intelligence Diagnostics & ITV-1 and IPF...

Boe Rimes -
Enzolytics Inc (OTCMKTS: ENZC) is making an explosive move up the charts after the Company announced a progress update and more on its future...
BioPharma

Enzolytics Inc (OTCMKTS: ENZC) Major Reversal Brewing as Biotech Gains Traction in HIV Market (Update on: ITV-1 EMA Approval, ITV-1, anti-HIV Treatment & IPF...

Boe Rimes -
Enzolytics Inc (OTCMKTS: ENZC) is easily one of the most exciting stocks currently trading on the OTCQB; trading 3 tenths of a penny over...
Energy & Resources

Enzolytics, Inc. (ENZC) Big Reversal Northbound as Biotech Launches IPF Immune & Plans Immune Therapeutic ITV-1 for Clinical Trials

Boe Rimes -
Enzolytics, Inc. (ENZC) is starting 2022 with a bang forming a massive reversal and rocketing up the charts on massive accumulation from investors and...
BioPharma

Top Covid Stocks In Play After Pfizer Vaccine Approval: TOMDF ENZC TSOI

Tom Rieder -
With the FDA approval of the Pfizer-BioNTech vaccination many biotech stocks moved higher.  Leading the microcaps was Todos Medical (OTCMKTS: TOMDF).  Shares of leading...
123Page 1 of 3

Latest news

© All rights reserved.

About Us

Popular Category

Editor Picks